Theramex has today launched Bijuva ®/ Bijuve ® across Europe and the UK. Real-world evidence, recognised by NICE and the British Menopause Society, suggests that use of body‑ identical ...

News of Bijuve’s availability on NHS Scotland follows BMS’s updated advice on HRT availability earlier this year. A body-identical HRT treatment, Bijuve ...

TherapeuticsMD, Inc., an innovative, leading women’ s healthcare company, and Theramex, a dedicated women’ s health company, announced that BIJUVE ® has received approval from the Medicines ...

Embargoed. London, 13 September 2022: Theramex has announced that the Scottish Medicines Consortium (SMC) has accepted Bijuve® (1mg estradiol / 100mg progesterone) for use across NHS Scotland. Bijuve® ...

Bijuva ®, (known as Bijuve ® in the UK), is the first, and only, body-identical hormone therapy treatment (HRT) for estrogen deficiency symptoms in post-menopausal women with intact uterus and at ...

TherapeuticsMD (NASDAQ:TXMD) stock is up on Friday after announcing approval for one of its treatments in two parts of Europe. Source: Shutterstock Bijuve is the treatment behind today’s news ...

The first and only body-identical HRT for post-menopausal oestrogen deficiency, Bijuve, has been passed by the SMC as suitable for use by Scotland’s National Health Service, after being advised ...

TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative, leading women’s healthcare company, and Theramex, a dedicated women’s health company, announced that BIJUVE ® has received approval from ...

PRESCRIBING INFORMATION IS AVAILABLE AT THE END OF THIS RELEASE FOR MEDICAL BUSINESS HEALTHCARE INDUSTRY TRADE MEDIA ONLY Theramex has today launched Bijuva Bijuve (1mg estradiol 100mg progesterone) ...

TherapeuticsMD (NASDAQ:TXMD) stock is up on Friday after announcing approval for one of its treatments in two parts of Europe. Source: Shutterstock Bijuve is the treatment behind today’s news ...